Emergent BioSolutions Inc. (EBS) shareholders
EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/3072% below fair value
$5.79−0.10 (-1.70%)
Close on Nov 13, 2026Market cap $296.87MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
87.1%
45M of 51M shares
Institutional holders
195
33 new, 26 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
0 buys · 13 sales
Net sold $986.09K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 4,651,339 | 9.00% | 13G (passive) amendment | Jun 30, 2026 |
| Oak Hill Advisors, L.P. | 3,613,338 | 6.39% | 13G (passive) | Sep 30, 2024 |
| Stowers Institute for Medical Research Joint filing with American Century Investment Management, Inc. (5.40%), American Century Companies, Inc. (5.40%) and 1 more | 2,770,448 | 5.40% | 13G (passive) | Jun 30, 2026 |
| Dimensional Fund Advisors LP | 2,757,158 | 5.30% | 13G (passive) | Mar 31, 2026 |
| State Street Corporation | 2,696,375 | 5.10% | 13G (passive) | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of EBS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 4,716,599 | 9.20% | $39.53M | +375,137 | 0.00% |
| Dimensional Fund Advisors LP | 3,076,646 | 6.00% | $25.78M | +319,488 | 0.00% |
| State Street Corp | 2,929,238 | 5.71% | $24.56M | +79,537 | 0.00% |
| American Century Companies Inc | 2,770,448 | 5.40% | $23.22M | +344,726 | 0.01% |
| Vanguard Capital Management LLC | 2,198,839 | 4.29% | $18.43M | −59,156 | 0.00% |
| Lsv Asset Management | 1,695,851 | 3.31% | $14.21M | +799,151 | 0.03% |
| Acadian Asset Management LLC | 1,344,323 | 2.62% | $11.26M | −37,301 | 0.01% |
| Geode Capital Management, LLC | 1,337,243 | 2.61% | $11.21M | +64,334 | 0.00% |
| Charles Schwab Investment Management Inc | 1,200,791 | 2.34% | $10.06M | −305,284 | 0.00% |
| Oak Hill Advisors LP | 1,113,338 | 2.17% | $9.33M | – | 1.33% |
| Millennium Management LLC | 1,072,185 | 2.09% | $8.98M | +540,184 | 0.00% |
| Ancora Advisors, LLC | 1,067,867 | 2.08% | $8.95M | +658,600 | 0.17% |
| Aqr Capital Management LLC | 1,041,151 | 2.03% | $8.72M | +51,474 | 0.00% |
| Goldman Sachs Group Inc | 1,035,421 | 2.02% | $8.68M | +223,861 | 0.00% |
| Vanguard Portfolio Management LLC | 1,029,371 | 2.01% | $8.63M | −87,907 | 0.00% |
| D. E. Shaw & Co., Inc. | 900,108 | 1.76% | $7.54M | −103,804 | 0.00% |
| Russell Investments Group, Ltd. | 859,482 | 1.68% | $7.20M | +523,584 | 0.01% |
| Federated Hermes, Inc. | 831,125 | 1.62% | $6.96M | +374,806 | 0.01% |
| Prudential Financial Inc | 805,895 | 1.57% | $6.75M | +357,080 | 0.01% |
| Prescott Group Capital Management, L.L.C. | 772,771 | 1.51% | $6.48M | – | 0.56% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 195 | 45M | 87.1% | 33 / 69 | 63 / 26 | 7M | 5M |
| Q1 2026 | 190 | 43M | 84.7% | 37 / 69 | 54 / 26 | 10M | 6M |
| Q4 2025 | 183 | 44M | 84.9% | 42 / 61 | 51 / 25 | 5M | 4M |
| Q3 2025 | 169 | 42M | 81.4% | 37 / 49 | 53 / 29 | 6M | 4M |
| Q2 2025 | 161 | 40M | 77.4% | 41 / 54 | 40 / 40 | 11M | 7M |
| Q1 2025 | 161 | 36M | 70.7% | 35 / 53 | 40 / 28 | 7M | 6M |
| Q4 2024 | 156 | 35M | 67.8% | 37 / 46 | 36 / 21 | 7M | 4M |
| Q3 2024 | 140 | 32M | 61.8% | 33 / 30 | 50 / 31 | 12M | 7M |
| Q2 2024 | 141 | 31M | 60.6% | 49 / 35 | 36 / 29 | 7M | 15M |
| Q1 2024 | 121 | 39M | 75.7% | 20 / 30 | 46 / 33 | 10M | 13M |
| Q4 2023 | 134 | 42M | 82.3% | 19 / 47 | 43 / 46 | 10M | 9M |
| Q3 2023 | 162 | 41M | 80.3% | 26 / 47 | 54 / 46 | 10M | 15M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
194 funds held EBS in Q2 2026, 52% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of EBS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Avantis U.S. Small Cap Value ETF | 2,270,234 | 4.43% | $20.70M | 0.08% | May 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,706,238 | 3.33% | $14.30M | 0.13% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,554,116 | 3.03% | $13.02M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,382,590 | 2.70% | $11.59M | 0.01% | Jun 30, 2026 |
| Schwab Fundamental U.S. Small Company ETF | 757,640 | 1.48% | $6.91M | 0.08% | May 31, 2026 |
| U.S. Small Cap Value Portfolio | 705,560 | 1.38% | $5.09M | 0.03% | Jul 31, 2026 |
| Federated Hermes MDT Small Cap Core Fund | 630,315 | 1.23% | $4.55M | 0.20% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 592,784 | 1.16% | $4.97M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 569,090 | 1.11% | $4.11M | 0.01% | Jul 31, 2026 |
| Vanguard Strategic Equity Fund | 528,566 | 1.03% | $4.43M | 0.04% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 502,380 | 0.98% | $4.21M | 0.03% | Jun 30, 2026 |
| U.S. Targeted Value Portfolio | 443,468 | 0.86% | $3.20M | 0.02% | Jul 31, 2026 |
| Dimensional U.S. Targeted Value ETF | 374,907 | 0.73% | $2.71M | 0.02% | Jul 31, 2026 |
| PIMCO RAE US Small Fund | 350,629 | 0.68% | $2.94M | 0.08% | Jun 30, 2026 |
| iShares Biotechnology ETF | 343,571 | 0.67% | $2.88M | 0.03% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Zsolt Harsanyi | Chairman, Director | 149,076 | 0.29% | May 4, 2026 |
| Joseph C. Papa | President and CEO, Director | 493,153 | 0.96% | May 1, 2026 |
| Paul Anthony Williams | SVP, Products Business | 156,098 | 0.30% | Oct 5, 2026 |
| Stephanie Duatschek | EVP, CGO | 197,416 | 0.39% | Aug 12, 2026 |
| Richard S. Lindahl | EVP, Chief Financial Officer | 374,083 | 0.73% | Jun 10, 2026 |
| Coleen Glessner | EVP, Quality & Ethics, and CPL | 202,201 | 0.39% | Jun 10, 2026 |
| William Hartzel | SVP, Bioservices | 185,558 | 0.36% | Jun 10, 2026 |
| Jessica Perl | SVP, General Counsel, Corp Sec | 165,286 | 0.32% | May 1, 2026 |
| Simon C. Lowry | SVP, R&D, CMO | 177,914 | 0.35% | May 1, 2026 |
| Donald W. DeGolyer | Director | 111,921 | 0.22% | Oct 7, 2026 |
| John D. Fowler Jr | Director | 30,350 | 0.06% | May 4, 2026 |
| Marvin L. White | Director | 113,839 | 0.22% | May 4, 2026 |
| Ronald Richard | Director | 123,761 | 0.24% | May 4, 2026 |
| Keith Katkin | Director | 96,294 | 0.19% | May 4, 2026 |
| Kathryn C. Zoon | Director | 80,998 | 0.16% | May 4, 2026 |
| Neal Franklin Fowler | Director | 160,847 | 0.31% | May 4, 2026 |
| Sujata Tyagi Dayal | Director | 101,543 | 0.20% | May 4, 2026 |
| Louis W. Sullivan | Director | 139,098 | 0.27% | May 2, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Donald W. DeGolyer Director | Oct 7, 2026 | Sale(10b5-1 plan) | −17,800 | $7.09 | $126.20K | 111,921 |
| Paul Anthony Williams SVP, Products Business | Oct 1, 2026 | Sale(10b5-1 plan) | −3,000 | $6.53 | $19.59K | 156,098 |
| Paul Anthony Williams SVP, Products Business | Jul 1, 2026 | Sale(10b5-1 plan) | −3,000 | $8.40 | $25.20K | 159,098 |
| Paul Anthony Williams SVP, Products Business | Jun 8, 2026 | Tax withholding | −694 | $8.00 | $5.55K | 162,098 |
| William Hartzel SVP, Bioservices | Jun 8, 2026 | Tax withholding | −1,741 | $8.00 | $13.93K | 185,558 |
| Richard S. Lindahl EVP, Chief Financial Officer | Jun 8, 2026 | Tax withholding | −3,964 | $8.00 | $31.71K | 374,083 |
| Coleen Glessner EVP, Quality & Ethics, and CPL | Jun 8, 2026 | Tax withholding | −2,018 | $8.00 | $16.14K | 202,201 |
| Sujata Tyagi Dayal Director | May 1, 2026 | Sale(10b5-1 plan) | −12,781 | $8.36 | $106.85K | 101,543 |
| Sujata Tyagi Dayal Director | May 1, 2026 | Sale(10b5-1 plan) | −980 | $8.94 | $8.76K | 100,563 |
| Donald W. DeGolyer Director | May 1, 2026 | Sale(10b5-1 plan) | −14,527 | $8.36 | $121.45K | 130,675 |
| Donald W. DeGolyer Director | May 1, 2026 | Sale(10b5-1 plan) | −954 | $8.96 | $8.55K | 129,721 |
| Kathryn C. Zoon Director | May 1, 2026 | Sale(10b5-1 plan) | −16,145 | $8.36 | $134.97K | 80,998 |
| Kathryn C. Zoon Director | May 1, 2026 | Sale(10b5-1 plan) | −1,057 | $8.97 | $9.48K | 79,941 |
| Sujata Tyagi Dayal Director | Apr 30, 2026 | Award | +25,344 | – | – | 114,324 |
| Keith Katkin Director | Apr 30, 2026 | Sale(10b5-1 plan) | −15,481 | $8.28 | $128.18K | 96,294 |
| Keith Katkin Director | Apr 30, 2026 | Award | +25,344 | – | – | 111,775 |
| Ronald Richard Director | Apr 30, 2026 | Award | +25,344 | – | – | 123,761 |
| Neal Franklin Fowler Director | Apr 30, 2026 | Award | +25,344 | – | – | 160,847 |
| Donald W. DeGolyer Director | Apr 30, 2026 | Award | +25,344 | – | – | 145,202 |
| Marvin L. White Director | Apr 30, 2026 | Award | +25,344 | – | – | 113,839 |
| Kathryn C. Zoon Director | Apr 30, 2026 | Award | +25,344 | – | – | 97,143 |
| John D. Fowler Jr Director | Apr 30, 2026 | Award | +25,344 | – | – | 30,350 |
| Zsolt Harsanyi Chairman, Director | Apr 30, 2026 | Award | +25,344 | – | – | 149,076 |
| Paul Anthony Williams SVP, Products Business | Apr 29, 2026 | Award | +100,111 | – | – | 162,792 |
| Joseph C. Papa President and CEO, Director | Apr 29, 2026 | Award | +187,708 | – | – | 493,153 |
| Jessica Perl SVP, General Counsel, Corp Sec | Apr 29, 2026 | Award | +104,282 | – | – | 165,286 |
| William Hartzel SVP, Bioservices | Apr 29, 2026 | Award | +100,111 | – | – | 187,299 |
| Coleen Glessner EVP, Quality & Ethics, and CPL | Apr 29, 2026 | Award | +100,111 | – | – | 204,219 |
| Richard S. Lindahl EVP, Chief Financial Officer | Apr 29, 2026 | Award | +162,680 | – | – | 378,047 |
| Simon C. Lowry SVP, R&D, CMO | Apr 29, 2026 | Award | +100,111 | – | – | 177,914 |
| Paul Anthony Williams SVP, Products Business | Apr 1, 2026 | Sale(10b5-1 plan) | −4,000 | $8.44 | $33.76K | 62,681 |
| Paul Anthony Williams SVP, Products Business | Mar 5, 2026 | Tax withholding | −9,397 | $8.44 | $79.31K | 66,681 |
| Jessica Perl SVP, General Counsel, Corp Sec | Mar 5, 2026 | Tax withholding | −6,465 | $8.44 | $54.56K | 61,004 |
| Joseph C. Papa President and CEO, Director | Mar 5, 2026 | Tax withholding | −37,055 | $8.44 | $312.74K | 305,445 |
| William Hartzel SVP, Bioservices | Mar 5, 2026 | Tax withholding | −9,493 | $8.44 | $80.12K | 87,188 |
| Coleen Glessner EVP, Quality & Ethics, and CPL | Mar 5, 2026 | Tax withholding | −8,199 | $8.44 | $69.20K | 104,108 |
| Richard S. Lindahl EVP, Chief Financial Officer | Mar 5, 2026 | Tax withholding | −23,650 | $8.44 | $199.61K | 215,367 |
| Simon C. Lowry SVP, R&D, CMO | Mar 5, 2026 | Tax withholding | −10,636 | $8.44 | $89.77K | 77,803 |
| John D. Fowler Jr Director | Mar 3, 2026 | Award | +5,006 | $8.99 | $45.00K | 5,006 |
| Coleen Glessner EVP, Quality & Ethics, and CPL | Mar 1, 2026 | Tax withholding | −313 | $8.15 | $2.55K | 112,307 |
| Paul Anthony Williams SVP, Products Business | Mar 1, 2026 | Tax withholding | −116 | $8.15 | $945 | 76,078 |
| Richard S. Lindahl EVP, Chief Financial Officer | Mar 1, 2026 | Tax withholding | −683 | $8.15 | $5.57K | 239,017 |
| Jessica Perl SVP, General Counsel, Corp Sec | Feb 9, 2026 | Tax withholding | −918 | $11.03 | $10.13K | 67,469 |
| William Hartzel SVP, Bioservices | Feb 6, 2026 | Tax withholding | −630 | $10.92 | $6.88K | 96,681 |
| William Hartzel SVP, Bioservices | Feb 6, 2026 | Returned to company | −5,771 | $10.92 | $63.02K | 97,311 |
| Paul Anthony Williams SVP, Products Business | Feb 6, 2026 | Tax withholding | −1,022 | $10.92 | $11.16K | 76,194 |
| Paul Anthony Williams SVP, Products Business | Feb 6, 2026 | Returned to company | −8,655 | $10.92 | $94.51K | 77,216 |
| Coleen Glessner EVP, Quality & Ethics, and CPL | Feb 6, 2026 | Tax withholding | −2,852 | $10.92 | $31.14K | 112,620 |
| Coleen Glessner EVP, Quality & Ethics, and CPL | Feb 6, 2026 | Returned to company | −28,847 | $10.92 | $315.01K | 115,472 |
| Richard S. Lindahl EVP, Chief Financial Officer | Feb 6, 2026 | Tax withholding | −5,642 | $10.92 | $61.61K | 239,700 |
| Richard S. Lindahl EVP, Chief Financial Officer | Feb 6, 2026 | Returned to company | −46,155 | $10.92 | $504.01K | 245,342 |
| Simon C. Lowry SVP, R&D, CMO | Dec 14, 2025 | Tax withholding | −3,543 | $11.41 | $40.43K | 88,439 |
| Ronald Richard Director | Dec 5, 2025 | Sale | −7,100 | $12.11 | $85.98K | 98,417 |
| Ronald Richard Director | Dec 5, 2025 | Option exercise | +25,748 | $5.02 | $129.25K | 124,165 |
| Ronald Richard Director | Dec 5, 2025 | Tax withholding | −10,864 | $11.90 | $129.28K | 113,301 |
| Ronald Richard Director | Dec 5, 2025 | Sale | −14,884 | $11.90 | $177.12K | 98,417 |
| William Hartzel SVP, Bioservices | Nov 11, 2025 | Tax withholding | −610 | $10.88 | $6.64K | 103,082 |
| Donald W. DeGolyer Director | Nov 10, 2025 | Sale(10b5-1 plan) | −17,801 | $10.54 | $187.62K | 119,858 |
| Sujata Tyagi Dayal Director | Nov 7, 2025 | Sale(10b5-1 plan) | −8,552 | $10.00 | $85.52K | 88,980 |
| Richard S. Lindahl EVP, Chief Financial Officer | Oct 15, 2025 | Tax withholding | −4,995 | $9.60 | $47.95K | 291,497 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
20.91%
10M shares short
Days to cover
10.1
At 1M shares a day
Change since last report
+4.1%
From 10M shares
Short volume, 20 days
58.4%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Emergent BioSolutions's stock actually held short. Settlement fails (shares not delivered on time) peaked at 31,398 shares on Sep 3, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Donald W. DeGolyer Director | Oct 7, 2026 | 17,800 | $126.12K | Oct 7, 2026 | Restricted Stock |
| Paul Anthony Williams Officer | Oct 1, 2026 | 3,000 | $19.59K | Oct 1, 2026 | Restricted Stock |
| Paul Anthony Williams Officer | Jul 1, 2026 | 3,000 | $25.21K | Jul 1, 2026 | Restricted Stock |
| Kathryn C. Zoon Director | May 1, 2026 | 17,202 | $144.49K | May 1, 2026 | Restricted Stock |
| Sujata Tyagi Dayal Director | May 1, 2026 | 13,761 | $115.61K | May 1, 2026 | Restricted Stock |
| Donald W. DeGolyer Director | May 1, 2026 | 15,481 | $130.06K | May 1, 2026 | Restricted Stock |
| Keith Katkin Director | Apr 30, 2026 | 15,481 | $128.14K | Apr 30, 2026 | Restricted Stock |
| Paul Anthony Williams Officer | Apr 1, 2026 | 4,000 | $33.78K | Apr 1, 2026 | Restricted Stock |
| Louis W. Sullivan Director | Jan 7, 2026 | 25,748 | $360.14K | Jan 7, 2026 | Stock Option Exercise |
| Louis W. Sullivan Director | Dec 22, 2025 | 104,695 | $1.34M | Dec 22, 2025 | Restricted Stock |
| Ronald Richard Director | Dec 5, 2025 | 32,848 | $392.33K | Dec 5, 2025 | Restricted Stock |
| Donald W. DeGolyer Director | Nov 10, 2025 | 17,801 | $187.54K | Nov 10, 2025 | Restricted Stock |
| Sujata Tyagi Dayal Director | Nov 7, 2025 | 8,552 | $85.52K | Nov 7, 2025 | Restricted Stock |
| Coleen Glessner Officer | Oct 7, 2025 | 30,608 | $306.08K | Oct 7, 2025 | Restricted Stock |
| Kathryn C. Zoon Director | Aug 15, 2025 | 7,086 | $62.85K | Aug 15, 2025 | Restricted Stock |
See a number that looks wrong?